New and emerging treatment options for multiple sclerosis (Q35207001)

7 August 2017

1 reference

title

New and emerging treatment options for multiple sclerosis (English)

1 reference

7 August 2017

0 references

Chris H Polman

1 reference

7 August 2017

Bernard M J Uitdehaag

series ordinal

1 reference

7 August 2017

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

563-566

1 reference

Interferons in relapsing remitting multiple sclerosis: a systematic review

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

The ups and downs of multiple sclerosis therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Treatment of multiple sclerosis with the pregnancy hormone estriol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Innate and adaptive immune responses can be beneficial for CNS repair

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900505-2

7 January 2021

10.1016/S1474-4422(03)00505-2

Identifiers

DOI

1 reference

7 August 2017

1 reference